Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more

855 Oak Grove Avenue, Menlo Park, CA, 94025, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

1.613B

52 Wk Range

$5.49 - $36.51

Previous Close

$33.32

Open

$33.49

Volume

432,875

Day Range

$33.49 - $36.29

Enterprise Value

604.9M

Cash

349.2M

Avg Qtr Burn

-21.6M

Insider Ownership

3.57%

Institutional Own.

-

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.